

FORM PTO-1390 (Modified) (REV 11-98)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER 2727-102
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR 1.5)		09/508238
INTERNATIONAL APPLICATION NO. PCT/EP98/05738	INTERNATIONAL FILING DATE 09 September 1998 (09.09.1998)	PRIORITY DATE CLAIMED 09 September 1997 (09.09.1997)		
TITLE OF INVENTION "Amino Acid Sequences and Method for Isolating Bacteria from the Type Genus Pseudomonas"				
APPLICANT(S) FOR DO/EO/US Cornelia Berghof, Alexander Gasch, Anja Braeuer, Cordt Groenewald, Freimut Wilborn, Arndt Rolfs				
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:				
<ol style="list-style-type: none"> 1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 3. <input type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1). 4. <input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date. 5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371 (c) (2)) <ol style="list-style-type: none"> a. <input checked="" type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau). b. <input type="checkbox"/> has been transmitted by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). 6. <input checked="" type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)). 7. <input checked="" type="checkbox"/> A copy of the International Search Report (PCT/ISA/210). 8. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3)) <ol style="list-style-type: none"> a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau). b. <input type="checkbox"/> have been transmitted by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input checked="" type="checkbox"/> have not been made and will not be made. 9. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 10. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)). 11. <input checked="" type="checkbox"/> A copy of the International Preliminary Examination Report (PCT/IPEA/409). 12. <input checked="" type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)). 				
Items 13 to 20 below concern document(s) or information included: <ol style="list-style-type: none"> 13. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 14. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 15. <input checked="" type="checkbox"/> A FIRST preliminary amendment. 16. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. 17. <input type="checkbox"/> A substitute specification. 18. <input type="checkbox"/> A change of power of attorney and/or address letter. 19. <input type="checkbox"/> Certificate of Mailing by Express Mail 20. <input checked="" type="checkbox"/> Other items or information: 				
Sequence Listing WIPO Publication first page Declaration of inventors (unsigned)				

U.S. APPLICATION NO. (IF FILING UNDER 37 CFR 1.5) **09/508238**

INTERNATIONAL APPLICATION NO.

PCT/EP98/05738

ATTORNEY'S DOCKET NUMBER

2727-102

21. The following fees are submitted:.

BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) :

- | | |
|---|----------|
| <input type="checkbox"/> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2) paid to USPTO and International Search Report not prepared by the EPO or JPO | \$970.00 |
| <input checked="" type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO | \$840.00 |
| <input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO | \$690.00 |
| <input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4) | \$670.00 |
| <input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) | \$96.00 |

ENTER APPROPRIATE BASIC FEE AMOUNT =**\$840.00**Surcharge of **\$130.00** for furnishing the oath or declaration later than 20 30**\$0.00**

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	
Total claims	18 - 20 =	0	x \$18.00	\$0.00
Independent claims	3 - 3 =	0 -	x \$78.00	\$0.00

Multiple Dependent Claims (check if applicable).

\$0.00**TOTAL OF ABOVE CALCULATIONS =** **\$840.00**

Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28) (check if applicable).

\$0.00**SUBTOTAL =** **\$840.00**Processing fee of **\$130.00** for furnishing the English translation later than 20 30**\$0.00****TOTAL NATIONAL FEE =** **\$840.00**

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable).

\$0.00**TOTAL FEES ENCLOSED =** **\$840.00**Amount to be:
refunded \$
charged \$ A check in the amount of

to cover the above fees is enclosed.

 Please charge my Deposit Account

501145 in the amount of \$840.00

A duplicate copy of this sheet is enclosed.

(Order No. 2727-102)

to cover the above fees.


 The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Deposit Account No. 501145 A duplicate copy of this sheet is enclosed.**(Order No. 2727-102)**

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Ronald R. Santucci
 Registration No. 28,988
 Pitney, Hardin, Kipp & Szuch, LLP
 711 Third Avenue, 20th Floor
 New York, New York 10017

(212)687-6000


 SIGNATURE

Ronald R. Santucci

NAME

28,988

REGISTRATION NUMBER

March 9, 2000

DATE

09/508238
514 Rec'd PCT/PTO 09 MAR 2000

2727-102

IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (US/DO/EO)

Applicants: Cornelia Berghof, Alexander Gasch, Anja Braeuer,
Cordt Groenewald, Freimut Wilborn, Arndt Rolfs

International Appln. No.: PCT/EP98/05738

International Filing Date: September 9, 1998

Priority Date Claimed: September 9, 1997

For: AMINO ACID SEQUENCES AND METHOD FOR ISOLATING BACTERIES FROM
THE TYPE GENUS PSEUDOMONAS

PRELIMINARY AMENDMENT

Box PCT
Commissioner for Patents
Washington, D.C. 20231
Attn: DO/EO/US

S I R:

Preliminary to examination of the above-identified
application kindly amend the application as follows:

In the Claims:

In claim 7, lines 1-2, kindly delete "one of the preceding
claims" and substitute therefor --claim 1--;

In claim 8, lines 1-2, kindly delete "one of the preceding
claims" and substitute therefor --claim 1--;

In claim 10, line 1, kindly delete "or 9";

In claim 11, lines 1-2, kindly delete "one of the preceding
claims" and substitute therefor --claim 1--;

In claim 12, line 2, kindly delete "one of claims 1 to 10"
and substitute therefor --claim 1--;

560940A01030900


In claim 15, line 1, kindly delete "one of claims 12 to 14" and substitute therefor --claim 12--;

In claim 17, line 1, kindly delete "one of claims 12 to 16" and substitute therefor --claim 12--.

REMARKS

The claims of the above-identified application (the claims as amended under Article 34 of the PCT) have been amended to remove all multiple dependencies. No new matter has been added. Accordingly, an early examination of the application is respectfully requested.

Respectfully submitted,


Ronald R. Santucci
Registration No. 28,988

Pitney, Hardin, Kipp & Szuch, LLP
711 Third Avenue, 20th Floor
New York, New York 10017
212-687-6000

U.S 10600

Page 1 of 2

VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS (37 CFR 1.9(i) AND 1.27 (e)) - SMALL BUSINESS CONCERN				Docket No. 2727-102
Serial No. 09/508,238	Filing Date	Patent No.	Issue Date	
Applicant/ Patentee: Cornelia Bergfeld, Alexander Gutsch, Anja Brueckner, Cordt Groenewald, Franka Wilborn and Arndt Reiß				
Invention: "Amino Acid Sequences and Method for Isolating Bacteria from the Type genus <i>Pseudomonas</i> ".				
<p>I hereby declare that I am:</p> <p><input type="checkbox"/> the owner of the small business concern identified below;</p> <p><input checked="" type="checkbox"/> an official of the small business concern empowered to act on behalf of the concern identified below;</p>				
<p>NAME OF CONCERN: Biopaxx Gesellschaft fuer Biotechnologische Entwicklung und Consulting mbH ADDRESS OF CONCERN: Tegeler Weg 33, D-10589 Berlin, Germany</p>				
<p>I hereby declare that the above-identified small business concern qualifies as a small business concern as defined in 13 CFR 121.3-18, and reproduced in 37 CFR 1.9(d), for purposes of paying reduced fees under Section 41(a) and (b) of Title 35, United States Code, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third party or parties controls or has the power to control both.</p>				
<p>I hereby declare that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the above identified invention described in:</p> <p><input type="checkbox"/> the specification filed herewith with title as listed above.</p> <p><input checked="" type="checkbox"/> the application identified above.</p> <p><input type="checkbox"/> the patent identified above.</p>				
<p>If the rights held by the above-identified small business concern are not exclusive, each individual, concern or organization having rights to the invention is listed on the next page and no rights to the invention are held by any person, other than the inventor, who could not qualify as an independent inventor under 37 CFR 1.9(c) or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e).</p>				

Copyright 1999 Legrand

Patent Act

Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Each person, concern or organization to which I have assigned, granted, conveyed, or licensed or am under an obligation under contract or law to assign, grant, convey, or license any rights in the invention is listed below.

- no such person, concern or organization exists.
- each such person, concern or organization is listed below.

FULL NAME			
ADDRESS	<input type="checkbox"/> Individual	<input type="checkbox"/> Small Business Concern	<input type="checkbox"/> Nonprofit Organization
FULL NAME			
ADDRESS	<input type="checkbox"/> Individual	<input type="checkbox"/> Small Business Concern	<input type="checkbox"/> Nonprofit Organization
FULL NAME			
ADDRESS	<input type="checkbox"/> Individual	<input type="checkbox"/> Small Business Concern	<input type="checkbox"/> Nonprofit Organization
FULL NAME			
ADDRESS	<input type="checkbox"/> Individual	<input type="checkbox"/> Small Business Concern	<input type="checkbox"/> Nonprofit Organization

Separate verified statements are required from each named person, concern or organization having rights to the invention according to their status as small entities. (37 CFR 1.27)

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.26(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING:

K. Berglas

TITLE OF PERSON SIGNING

Directed

OTHER THAN OWNER:

ADDRESS OF PERSON SIGNING:

Tegeleer Weg 33
D-10589 Berlin
Germany

Frankfurt

SIGNATURE:

Berglas

DATE:

3/103/00

Patent and Trademark Office-U.S. DEPARTMENT OF COMMERCE

09/508238

514 Rec'd PCT/PTO 09 MAR 2000

- 1 -

**Nucleic acid sequences and processes for detecting bacteria
of the *Pseudomonas* genus**

The invention relates to nucleic acid molecules for detecting *Pseudomonas*, to a kit and to uses thereof.

General background of the invention

The gram-negative bacterium *Pseudomonas aeruginosa* is a widespread bacterium that is pathogenic for humans and that constitutes a major health risk especially to neonates and to people having weakened resistance. Besides its major clinical significance, the antibiotic resistances that are frequently present and the formation of toxins, especially the highly toxic exotoxin A (Woods, D.E. and Iglesias, B.H., Rev. Infect. Dis. 5, 714 - 722 (1983)), *Pseudomonas aeruginosa* is one of the most important bacterial causes of cases of food poisoning. Conventional processes require at least 4 days for the detection of *Pseudomonas aeruginosa*. There is

therefore an urgent need for the development of rapid processes for detecting *Pseudomonas aeruginosa* in food and in clinical samples.

In recent years, a number of new methods have been developed for routine use in detecting particular microorganisms. These include immunological processes based on the use of polyvalent or monoclonal antibodies and processes in which nucleic acid probes are used for detection by means of hybridisation to organism-specific nucleic acids. Further methods that have been described are those processes which are based on a specific nucleic acid amplification, with or without a subsequent confirmation reaction by nucleic acid hybridisation. Processes used for the amplification of nucleic acids are, for example, the polymerase chain reaction (PCR) [US Patents 4,683,195; 4,683,202; and 4,965,188], the ligase chain reaction [WO Publication 89/09835], "self-sustained sequence replication" [EP 329,822], the "transcription based amplification system" [EP 310,229] and the Q β RNA-replicase system [US Patent 4,957,858].

The mentioned nucleic-acid-based processes are so sensitive that, in contrast to conventional microbiological processes, it is possible to dispense with, or considerably curtail, a lengthy increase in quantity of the microorganism being detected from the sample under investigation. Testing for the presence or absence of the microorganism in question is therefore generally concluded within one day when using the mentioned nucleic-acid-based processes, thereby achieving a considerable reduction in time, especially when conventional processes require several days or weeks for detection.

Various PCR-based processes for the detection of *Pseudomonas aeruginosa* have been described. By amplifying a region of DNA having a length of 369 bp from the exotoxin A gene it has been possible to detect the presence of strains of the species *Pseudomonas aeruginosa* selectively [Khan et al. (1994), Appl. Environ. Microbiol. 60, 3739-3745]. Even though no bacteria of other species were detected using that PCR system, an amplified product was observed in only 96 % of the 130 *Pseudomonas aeruginosa* strains tested in total. Consequently, that PCR system is of only limited suitability for establishing a rapid process by means of which the presence of all strains of *Pseudomonas aeruginosa* can be detected reliably.

With the aid of a further, recently published process based on a multiplex PCR it has been possible to detect, selectively, fluorescent pseudomonads on the one hand and *Pseudomonas aeruginosa* on the other hand [De Vos et al. (1997), J. Clin. Microbiol. 35, 1295-1299]. Using that process, it was possible to detect each of the 150 isolates of *Pseudomonas aeruginosa* tested in total. It is, however, disadvantageous that the oprL gene used for the selective detection of *Pseudomonas aeruginosa* is also highly conserved in other species of the *Pseudomonas* genus. Thus, the amino acids that are coded for in the region of the binding sites of the primers used by Voss et al. are identical in *Pseudomonas putida* and *Pseudomonas aeruginosa*. The detection of *Pseudomonas aeruginosa* is accordingly based merely on a few different base pairs caused by the variation in the third position of particular amino acid codons, which on the basis of experience carries a high risk of false-positive and/or false-negative results occurring.

In addition, because of the high degree of conservation of the oprI and oprL genes, the multiplex PCR system described is unlikely to offer a possible means of detecting - for example by the use of various probes subsequently to the PCR reaction - other clinically significant species of the *Pseudomonas* genus, such as, for example, *Pseudomonas fluorescens*, *Pseudomonas mendocina*, *Pseudomonas putida* or *Pseudomonas stutzeri*.

An aim of the invention described herein was to establish nucleic acid sequences whose use as primers and/or probes would ensure detection, in as complete a manner as possible, of all representatives of the species *Pseudomonas aeruginosa*. A further aim of the invention was to identify a region of the genome having sufficiently high sequence variability within different species of the *Pseudomonas* genus to allow, optionally, the detection of other species of the *Pseudomonas* genus as well, for example by using different variants of primers and/or probes in the PCR or subsequently to the PCR.

Depending on the size of the group of microorganisms to be detected and the evolutionary relatedness (similarity) of microorganisms to be excluded (that are not to be detected), detection based on differential DNA sequences requires very extensive preliminary work in order to identify suitable DNA sequences that have the desired specificity in the particular case. The invention described herein relates to such DNA sequences, by means of which the rapid detection of bacteria of the *Pseudomonas* genus, especially of *Pseudomonas aeruginosa*, is possible.

Description of the invention

The problem underlying the invention is solved, according to one embodiment, by a nucleic acid molecule

that is obtainable by starting from a plurality of strains belonging to, on the one hand, a to-be-detected group of bacteria of the *Pseudomonas* genus and, on the other hand, not-to-be-detected bacteria,

- (a) isolating, in a manner known *per se*, genomic DNA from a *Pseudomonas* strain of those groups (first strain),
- (b) amplifying, in a manner known *per se*, the 23S/5S intergenic region, optionally together with the directly adjacent 23S region and/or the directly adjacent 5S region, and obtaining the amplification product (first amplification product),
- (c) in accordance with steps (a) and (b) in each case, isolating genomic DNA using a second, third, . . . and/or n^{th} *Pseudomonas* strain of those groups, amplifying the 23S/5S intergenic region, optionally together with the directly adjacent 23S region and/or the directly adjacent 5S region, and obtaining the amplification product (second, third, . . . n^{th} amplification product),
- (d) determining, in a manner known *per se*, the DNA sequence of amplification products obtained according to (b) and (c), and comparing the DNA sequence of the amplification product according to (b) with the DNA sequence of one or more amplification products according to (c), and
- (e) obtaining, as a primer or probe, in a manner known *per se*, a nucleic acid molecule by means of which the to-be-detected group of bacteria of the *Pseudomonas* genus can be distinguished from the not-to-be-detected group of bacteria of the *Pseudomonas* genus on the basis of differences at at least one nucleotide position in the sequence region of the nucleic acid molecule.

The nucleic acid molecule according to the invention can be obtainable by starting from strains belonging to, on the one hand, to-be-detected bacteria of the *Pseudomonas* genus and,

on the other hand, not-to-be-detected bacteria of a genus (genera) other than *Pseudomonas*.

The problem underlying the invention is solved, according to a further embodiment, by a nucleic acid molecule that is obtainable by starting from a plurality of strains belonging to a to-be-detected group and a not-to-be-detected group of bacteria of the *Pseudomonas* genus,

- (a) isolating, in a manner known *per se*, genomic DNA from a *Pseudomonas* strain of those groups (first strain),
- (b) amplifying, in a manner known *per se*, the 23S/5S intergenic region, optionally together with the directly adjacent 23S region and/or the directly adjacent 5S region, and obtaining the amplification product (first amplification product),
- (c) in accordance with steps (a) and (b) in each case, isolating genomic DNA using a second, third, . . . and/or n^{th} *Pseudomonas* strain of those groups, amplifying the 23S/5S intergenic region, optionally together with the directly adjacent 23S region and/or the directly adjacent 5S region, and obtaining the amplification product (second, third, . . . n^{th} amplification product),
- (d) determining, in a manner known *per se*, the DNA sequence of amplification products obtained according to (b) and (c), and comparing the DNA sequence of the amplification product according to (b) with the DNA sequence of one or more amplification products according to (c), and
- (e) obtaining, as a primer or probe, in a manner known *per se*, a nucleic acid molecule by means of which the to-be-detected group of bacteria of the *Pseudomonas* genus can be distinguished from the not-to-be-detected group of bacteria of the *Pseudomonas* genus on the basis of differences at at least one nucleotide position in the sequence region of the nucleic acid molecule.

The nucleic acid molecule according to the invention can be obtainable by starting from strains belonging to a to-be-detected group of bacteria of the species *Pseudomonas aeruginosa* and a not-to-be-detected group of bacteria of other species.

The invention relates also to a nucleic acid molecule of SEQ ID NO 1 or the sequence complementary thereto.

The invention relates also to a nucleic acid molecule of that kind, having a shortened sequence compared with the aforementioned nucleic acid molecule, namely the sequence of the region or in the region of the nucleotide positions 12 to 131.

The invention relates also to a nucleic acid molecule of that kind, having a shortened sequence compared with a nucleic acid molecule of SEQ ID NO 1, namely

- (i) SEQ ID NO 3 or
- (ii) SEQ ID NO 4 or
- (iii) SEQ ID NO 5 or
- (iv) the sequence complementary to each of (i), (ii) and (iii).

The invention relates also to a nucleic acid molecule of SEQ ID NO 2 or the sequence complementary thereto.

A nucleic acid molecule according to the invention may be characterised in that, in respect of its sequence in at least 10 successive nucleotides of its nucleotide chain,

- (i) it is identical to a nucleic acid molecule according to one of the preceding claims or

- (ii) it corresponds to a nucleic acid molecule according to one of the preceding claims in 9 out of 10 successive nucleotides or
- (iii) it corresponds to a nucleic acid molecule according to one of the preceding claims in 8 out of 10 successive nucleotides or
- (iv) it is at least 90 % homologous to a nucleic acid molecule according to one of the preceding claims.

Such a nucleic acid molecule according to the invention can be characterised in that it is from 10 to 250, and preferably from 15 to 30, nucleotides long.

A nucleic acid molecule according to the invention can be characterised in that it is single-stranded or double-stranded.

A nucleic acid molecule according to the invention can be characterised in that it is present

- (i) as DNA or
- (ii) as RNA corresponding to (i) or
- (iii) as PNA,

the nucleic acid molecule where appropriate having been modified in a manner known *per se* for analytical detection processes, especially those based on hybridisation and/or amplification.

Thus, a nucleic acid molecule according to the invention can have been modified in such a manner that up to 20% of the nucleotides of at least 10 successive nucleotides of its nucleotide chain, especially 1 or 2 nucleotides, have been replaced by analogous building blocks known *per se* as probes and/or primers, especially by nucleotides that do not occur naturally in bacteria.

The nucleic acid molecule according to the invention can also have been modified or labelled or additionally modified or labelled in such a manner that it comprises, in a manner known *per se* for analytical detection processes, one or more radioactive groups, coloured groups, fluorescent groups, groups for immobilisation on a solid phase and/or groups for an indirect or direct reaction, especially for an enzymatic reaction, preferably using antibodies, antigens, enzymes and/or substances having an affinity for enzymes or enzyme complexes, and/or otherwise modifying or modified groups of nucleic-acid-like structure.

According to a further embodiment, the problem underlying the invention is solved by a kit for analytical detection processes, especially for the detection of bacteria of the *Pseudomonas* genus, that kit being characterised by one or more nucleic acid molecules according to the invention.

According to a further embodiment, the problem underlying the invention is solved by use of one or more nucleic acid molecules according to the invention or of a kit according to the invention for detection of the presence or absence of bacteria belonging to a group of bacteria of the *Pseudomonas* genus.

The use according to the invention can be characterised in that the group of bacteria of the *Pseudomonas* genus includes various strains of *Pseudomonas aeruginosa* or is made up from those strains.

Such use according to the invention can be characterised in that the group of bacteria of the *Pseudomonas* genus is composed exclusively of *Pseudomonas aeruginosa* strains.

Use according to the invention can also be characterised in that nucleic acid hybridisation and/or nucleic acid amplification is/are carried out.

Use according to the invention can also be characterised in that, as nucleic acid amplification, a polymerase chain reaction is carried out.

Use according to the invention can also be characterised in that the detection is carried out by distinguishing the to-be-detected bacteria from not-to-be-detected bacteria on the basis of differences in the genomic DNA and/or RNA at at least one nucleotide position in the region of a nucleic acid molecule according to the invention.

Use according to the invention can also be characterised in that distinguishing is carried out on the basis of differences in the region of a nucleic acid molecule of SEQ ID NO 1 or of its complementary sequence.

To detect specific microorganisms by means of nucleic acid hybridisation or amplification, organism-specific oligonucleotides are, therefore, used according to the invention. **Organism-specific oligonucleotides** are nucleic acids, from 10 to 250 bases (preferably from 15 to 30 bases) long, the base sequence of which is characteristic of a specific microorganism or a group of microorganisms. When using such organism-specific oligonucleotides (for example, as primers or probes) with the processes mentioned hereinbefore, hybridisation to DNA/amplification of DNA can take place, under suitable reaction conditions, only when the DNA of the microorganisms to be detected in the particular case is present.

Prokaryotic ribosomes comprise three distinct nucleic acid components, which are generally known as 5S, 16S and 23S rRNA (ribosomal ribonucleic acid). The genetic information for those ribonucleic acids (rDNA) is arranged in the genome typically in the form of tandems. The organisation of such a unit is 16S-23S-5S, the three genes being separated from one another by short hypervariable intergenic regions. The units are present in the genome in several copies, it being possible for the number of the repeating units to vary in different bacteria. The high degree of conservation of the DNA sequence in the region of 16S rDNA, 23S rDNA and 5S rDNA across the entire kingdom of bacteria allows **non-specific oligonucleotides** to be designed, even without precise knowledge of the DNA sequences of the microorganisms to be investigated. Such non-specific oligonucleotides are characteristic of a relatively large group of microorganisms, which are generally phylogenetically related. By using those non-specific oligonucleotides it will be possible for the person skilled in the art, for example after appropriate preliminary tests by means of DNA amplification using PCR, to isolate rDNA fragments, for example the 23S/5S intergenic region, of any particular microorganism. By DNA sequencing, it is then possible to determine the sequence of the hypervariable intergenic regions of the microorganism in question.

DNA sequencing of the 23S/5S intergenic region of as large a number as possible of **to-be-detected** bacteria (e.g. of various *Pseudomonas* species), on the one hand, and subsequent comparison of those DNA sequences, on the other hand, allows DNA regions to be identified that in the group investigated (e.g. all *Pseudomonas* species) are not changed or only insignificantly changed.

DNA sequencing of the 23S/5S intergenic region of selected **not-to-be-detected** bacteria (e.g. bacteria that do not belong to the *Pseudomonas* genus), on the one hand, and subsequent comparison of those DNA sequences with the sequences of to-be-detected bacteria (e.g. various *Pseudomonas* species), on the other hand, allows DNA sequences to be identified that are characteristic of the to-be-detected bacteria (e.g. all *Pseudomonas* species). It is then possible to derive, from these DNA sequences, oligonucleotides that can be used as primers and/or probes in processes based on nucleic acids, with the aim of specifically detecting the group of bacteria in question (e.g. all species of the *Pseudomonas* genus).

The DNA sequences described in the present invention for detecting bacteria of the *Pseudomonas* genus, especially bacteria of the species *Pseudomonas aeruginosa*, are based on the 23S/5S intergenic region and the directly adjacent region of the 23S rDNA. The DNA sequence in that region was determined for a large number of bacteria. After exact sequence comparisons, organism-specific nucleic acid sequences were determined, which can be used for primers and/or probes for use in a species-/genus-specific detection process.

To detect the group of microorganisms in question, nucleic acids, preferably genomic DNA, are firstly released from the cells contained in a sample or bacterial culture to be investigated. By means of nucleic acid hybridisation, it is then possible - using the organism-specific oligonucleotides according to the invention as a probe - to **directly** detect organism-specific nucleic acids in the sample to be investigated. Various processes known to the person skilled

in the art are suitable for that purpose, such as, for example, "Southern blot" or "dot blot".

Preference is given, however, above all on account of the relatively high sensitivity, to an indirect detection process in which the DNA/RNA sequences sought are firstly amplified by means of the above-mentioned processes for amplifying nucleic acids, preferably PCR.

The amplification of DNA/RNA using the processes mentioned can be effected by using organism-specific oligonucleotides as primers, specific amplification products being formed only when DNA/RNA of the to-be-detected microorganism is present. The specificity of the detection process can be increased by a subsequent detection reaction using organism-specific oligonucleotides as probes. For that subsequent detection reaction it is also possible to use non-specific oligonucleotides.

Alternatively, the nucleic acid amplification can also be carried out in the presence of one or more non-specific oligonucleotides, so that it is possible that DNA/RNA of other, not-to-be-detected microorganisms may also be amplified. Such an amplification process is generally less specific and should therefore be backed up by a subsequent detection reaction using one or more organism-specific oligonucleotide(s) as probe(s).

Various processes by which the amplification products formed in the indirect processes can be detected will be known to the person skilled in the art. These include, *inter alia*, visualisation by means of gel electrophoresis, the hybridisation of probes on immobilised reaction products [coupled to nylon or nitrocellulose filters ("Southern

blots") or, for example, on beads or microtitre plates] and the hybridisation of the reaction products on immobilised probes (e.g. "reverse dot blots" or beads or microtitre plates coupled with probes).

A large number of different variants have been described by means of which organism-specific oligonucleotides (for example probes and primers) can be labelled or modified for the direct or indirect detection processes described. They may comprise, for example, radioactive, coloured, fluorescent or otherwise modified or modifying groups, for example antibodies, antigens, enzymes or other substances having an affinity for enzymes or enzyme complexes. Probes and primers may be either naturally occurring or synthetically produced double-stranded or single-stranded DNA or RNA or modified forms of DNA or RNA, such as, for example, PNA (in these molecules the sugar units have been replaced by amino acids or peptides). Particular nucleotides or a number of nucleotides of the probes or primers may be replaced by analogous building blocks (such as, for example, nucleotides that do not naturally occur in the target nucleic acid). In the case of the above-mentioned indirect detection processes, detection can be carried out also by means of an internally labelled amplification product. That can be effected, for example, by integrating modified nucleoside triphosphates (for example, coupled with digoxigenin or fluorescein) during the amplification reaction.

Suitable organism-specific oligonucleotides according to the invention are nucleic acids, preferably from 10 to 250 bases and especially from 15 to 30 bases long, that correspond, at least in a 10 base long sequence, to Sequences 1 to 5 mentioned hereinbelow or to their complementary sequences. Relatively small differences (1 or 2 bases) in that 10 base

long sequence are possible without the specificity mentioned in the particular case being lost in amplification and/or hybridisation. The person skilled in the art will know that in the case of such relatively small differences the reaction conditions will need to be altered accordingly; cf., for example, T. Maniatis, Molecular Cloning, Editors G. Sambrook & E.F. Fritsch, Cold Spring Harbour Laboratory Press, 1989.

The sequence of *Pseudomonas aeruginosa* (ATCC 10145) in the region of the 23S/5S intergenic region is:

(Sequence 1 = SEQ ID NO 1))

```
ATAAACACCCAAACAATCTGAYGATTGTGTTGTAAGGTGAAGTCGACGAACCGAAAGTCG  
CATGAACCGCAAACACCTTGAAATCACATACCTGAATCCGGATAGACGTAAGCCCAAGCGAA  
CGGATAT
```

In addition, the sequence in the region of the 23S/5S intergenic region was determined for 6 further strains of the species *Pseudomonas aeruginosa* and for at least one strain of each of the following species: *Pseudomonas asplenii*, *Pseudomonas citronellosis*, *Pseudomonas corrugata*, *Pseudomonas fluorescens*, *Pseudomonas fragi*, *Pseudomonas mendocina*, *Pseudomonas pseudoalcaligenes*, *Pseudomonas putida*, *Pseudomonas stutzeri*, *Pseudomonas syringae*. The sequence comparisons showed that a number of oligonucleotides derived from Sequence 1 are suitable for the selective detection of bacteria of the species *Pseudomonas aeruginosa*. The sequence of the region (12-131) is suitable for such organism-specific oligonucleotides.

From Sequence 1 there were derived the following oligonucleotides, which are especially suitable as primers for PCR (Sequence 3 and 5) and as a probe (Sequence 4).

Oligonucleotide Pal (Sequence 2) corresponds to position 2823-2842 of a 23S rRNA gene of *Pseudomonas aeruginosa* ATCC 10145 [Toschka et al. (1987), Nucleic Acids. Res. 15, 7182]:

Oligonucleotide Pal: (Sequence 2 = SEQ ID NO 2) 5'-
GATAGGCTGGGTGTGAAGC-3'

Oligonucleotide Pa2: (Sequence 3 = SEQ ID NO 3) 5'-
CTTGGGCTTACGTCTATCCG-3'

Oligonucleotide Pa3: (Sequence 4 = SEQ ID NO 4) 5'-
TTCAGGTATGTGATTCAAG GTG-3'

Oligonucleotide Pa4: (Sequence 5 = SEQ ID NO 5) 5'-
GACGATTGTGTGTTGTAAGGTGA

Example 1: Detection of bacteria of the species *Pseudomonas aeruginosa* using the polymerase chain reaction

DNA was isolated by standard processes from pure cultures of the bacteria listed in Table 1. Approximately from 10 to 100 ng of each of those DNA preparations was then used in the PCR in the presence of 0.4 µM of each of oligonucleotide Pa1 and Pa2 or Pa2 and Pa4, 200 µM of dNTP's (Boehringer Mannheim), 4 mM MgCl₂, 16 mM (NH₄)₂SO₄, 67 mM Tris/HCl (pH 8.8), 0.01% Tween 20 and 0.03 U/µl Taq-polymerase (Biomaster). The PCR was carried out in a Perkin-Elmer 9600 (Pa1 and Pa2)/Biometra TRIO-Thermoblock (Pa4 and Pa2) thermocycler using the following thermoprofiles:

a) amplification using oligonucleotide Pa1 and Pa2

- initial denaturing 95°C 5 min

- 1st amplification (15 cycles)	94°C	35 sec
	68°C	30 sec
	72°C	30 sec
- 2nd amplification (20 cycles)	94°C	35 sec
	64°C	30 sec
	72°C	30 sec
- final synthesis	72°C	5 min

b) amplification using oligonucleotide Pa4 and Pa2

- initial denaturing	95°C	5 min
- amplification (35 cycles)	95°C	30 sec
	62°C	30 sec
	72°C	20 sec
- final synthesis	72°C	5 min

After the end of the PCR reaction, the amplification products were separated by means of agarose gel electrophoresis and visualised by staining with ethidium bromide. The expected products having a length of 191 bp/102 bp were observed only in those cases in which DNA of strains of the species *Pseudomonas aeruginosa* was present (compare Table 1), but not in the presence of DNA of other tested bacteria. After the end of the run, the DNA contained in the gels was transferred by standard methods to nylon filters and hybridised with the oligonucleotide Pa3 (Sequence 4) biotinylated at the 5' terminus, in order to check the specificity. Hybridisation was effected in 5 x SSC, 2 % blocking reagent, 0.1 % lauryl sarcosine, 0.02 % SDS and 5 pmol/ml of probe for 4 hours at 48°C. Washing was carried out in 2 x SSC, 0.1 % SDS for 2 x

15 minutes at room temperature and in 2 x SSC, 0.1 % SDS for 1 x 15 minutes at 48°C. Detection was carried out according to standard methods using alkaline phosphatase conjugates (Extravidin, SIGMA, # E-2636) in the presence of 5-bromo-4-chloro-3-indolyl phosphate and 4-nitro-blue tetrazolium chloride (Boehringer Mannheim).

A band was observed on the filters only in those cases in which a band had previously been visible on the agarose gel (see Table 1). Thus, the presence of all the 86 tested *Pseudomonas aeruginosa* strains was detected by PCR and by hybridisation. In contrast, none of the tested bacterial strains not belonging to that species was detected using this system.

Table 1: Results of PCR amplification using the oligonucleotides Pa1/Pa2 (SEQ ID NO 2 and SEQ ID NO 3) and Pa4/Pa2 (SEQ ID NO 5 and SEQ ID NO 3) and subsequent hybridisation using the oligonucleotide Pa3 (SEQ ID NO 4).

Species	Designation of strain	Pa1/Pa2	Pa4/Pa2
<i>Pseudomonas aeruginosa</i>	ATCC 9027	+	+
<i>Pseudomonas aeruginosa</i>	ATCC 10145	+	+
<i>Pseudomonas aeruginosa</i>	ATCC 14886	+	+
<i>Pseudomonas aeruginosa</i>	ATCC 15522	+	+
<i>Pseudomonas aeruginosa</i>	ATCC 15691	+	+
<i>Pseudomonas aeruginosa</i>	ATCC 15692	+	+
<i>Pseudomonas aeruginosa</i>	ATCC 21472	+	+
<i>Pseudomonas aeruginosa</i>	ATCC 21776	+	+
<i>Pseudomonas aeruginosa</i>	ATCC 33350	+	+
<i>Pseudomonas aeruginosa</i>	ATCC 33361	+	+
<i>Pseudomonas aeruginosa</i>	ATCC 33818	+	+
<i>Pseudomonas aeruginosa</i>	ATCC 33988	+	+
<i>Pseudomonas aeruginosa</i>	LMG 8029	+	+
<i>Pseudomonas aeruginosa</i>	DSM 288	+	+
<i>Pseudomonas aeruginosa</i>	DSM 939	+	+
<i>Pseudomonas aeruginosa</i>	DSM 1117	+	+
<i>Pseudomonas aeruginosa</i>	DSM 1253	+	+
<i>Pseudomonas aeruginosa</i>	DSM 1299	+	+
<i>Pseudomonas aeruginosa</i>	BC 682	+	+
<i>Pseudomonas aeruginosa</i>	BC 4283	+	+
<i>Pseudomonas aeruginosa</i>	BC 4880	+	+

<i>Pseudomonas aeruginosa</i>	BC 4937	+	+
<i>Pseudomonas aeruginosa</i>	BC 4938	+	+
<i>Pseudomonas aeruginosa</i>	BC 5258	+	+
<i>Pseudomonas aeruginosa</i>	BC 5594	+	+
<i>Pseudomonas aeruginosa</i>	BC 5595	+	+
<i>Pseudomonas aeruginosa</i>	BC 5596	+	+
<i>Pseudomonas aeruginosa</i>	BC 5597	+	+
<i>Pseudomonas aeruginosa</i>	BC 5598	+	+
<i>Pseudomonas aeruginosa</i>	BC 5599	+	+
<i>Pseudomonas aeruginosa</i>	BC 5600	+	+
<i>Pseudomonas aeruginosa</i>	BC 5601	+	+
<i>Pseudomonas aeruginosa</i>	BC 5602	+	+
<i>Pseudomonas aeruginosa</i>	BC 5603	+	+
<i>Pseudomonas aeruginosa</i>	BC 5604	+	+
<i>Pseudomonas aeruginosa</i>	BC 5606	+	+
<i>Pseudomonas aeruginosa</i>	BC 5607	+	+
<i>Pseudomonas aeruginosa</i>	BC 5917	+	+
<i>Pseudomonas aeruginosa</i>	BC 5918	+	+
<i>Pseudomonas aeruginosa</i>	BC 5919	+	+
<i>Pseudomonas aeruginosa</i>	BC 5920	+	+
<i>Pseudomonas aeruginosa</i>	BC 5921	+	+
<i>Pseudomonas aeruginosa</i>	BC 5922	+	+
<i>Pseudomonas aeruginosa</i>	BC 5923	+	+
<i>Pseudomonas aeruginosa</i>	BC 5924	+	+
<i>Pseudomonas aeruginosa</i>	BC 5925	+	+
<i>Pseudomonas aeruginosa</i>	BC 5926	+	+
<i>Pseudomonas aeruginosa</i>	BC 5927	+	+
<i>Pseudomonas aeruginosa</i>	BC 5928	+	+
<i>Pseudomonas aeruginosa</i>	BC 5929	+	+
<i>Pseudomonas aeruginosa</i>	BC 5930	+	+
<i>Pseudomonas aeruginosa</i>	BC 5932	+	+
<i>Pseudomonas aeruginosa</i>	BC 5933	+	+
<i>Pseudomonas aeruginosa</i>	BC 5934	+	+
<i>Pseudomonas aeruginosa</i>	BC 7046	+	+
<i>Pseudomonas aeruginosa</i>	BC 7047	+	+
<i>Pseudomonas aeruginosa</i>	BC 7048	+	+
<i>Pseudomonas aeruginosa</i>	BC 7049	+	+
<i>Pseudomonas aeruginosa</i>	BC 7050	+	+
<i>Pseudomonas aeruginosa</i>	BC 7051	+	+
<i>Pseudomonas aeruginosa</i>	BC 7052	+	+
<i>Pseudomonas aeruginosa</i>	BC 7053	+	+
<i>Pseudomonas aeruginosa</i>	BC 7054	+	+
<i>Pseudomonas aeruginosa</i>	BC 7055	+	+
<i>Pseudomonas aeruginosa</i>	BC 7056	+	+
<i>Pseudomonas aeruginosa</i>	BC 7057	+	+
<i>Pseudomonas aeruginosa</i>	BC 7058	+	+
<i>Pseudomonas aeruginosa</i>	BC 7059	+	+
<i>Pseudomonas aeruginosa</i>	BC 7060	+	+
<i>Pseudomonas aeruginosa</i>	BC 7061	+	+
<i>Pseudomonas aeruginosa</i>	BC 7062	+	+

<i>Pseudomonas aeruginosa</i>	BC 7063	+	+
<i>Pseudomonas aeruginosa</i>	BC 7064	+	+
<i>Pseudomonas aeruginosa</i>	BC 7065	+	+
<i>Pseudomonas aeruginosa</i>	BC 7066	+	+
<i>Pseudomonas aeruginosa</i>	BC 7067	+	+
<i>Pseudomonas aeruginosa</i>	BC 7068	+	+
<i>Pseudomonas aeruginosa</i>	BC 7069	+	+
<i>Pseudomonas aeruginosa</i>	BC 7070	+	+
<i>Pseudomonas aeruginosa</i>	BC 7071	+	+
<i>Pseudomonas aeruginosa</i>	BC 7072	+	+
<i>Pseudomonas aeruginosa</i>	BC 7073	+	+
<i>Pseudomonas aeruginosa</i>	BC 7474	n.p.	+
<i>Pseudomonas aeruginosa</i>	BC 7475	n.p.	+
<i>Pseudomonas aeruginosa</i>	BC 8468	n.p.	+
<i>Pseudomonas aeruginosa</i>	BC 8493	n.p.	+
<i>Pseudomonas alcaligenes</i>	DSM 50342	-	-
<i>Pseudomonas asplenii</i>	DSM 50254	-	-
<i>Pseudomonas cepacia</i>	BC 3134	-	-
<i>Pseudomonas chlororaphis</i>	BC 1753	-	-
<i>Pseudomonas citronellosis</i>	DSM 50332	-	-
<i>Pseudomonas corrugata</i>	DSM 7228	-	-
<i>Pseudomonas fluorescens</i>	BC 950	n.p.	-
<i>Pseudomonas fluorescens</i>	BC 4882	-	-
<i>Pseudomonas fluorescens</i>	BC 2439	-	-
<i>Pseudomonas fragi</i>	DSM 3456	-	-
<i>Pseudomonas indigofera</i>	BC 1105	n.p.	-
<i>Pseudomonas mendocina</i>	DSM 50017	-	-
<i>Pseudomonas oleovorans</i>	DSM 1045	-	-
<i>Pseudomonas pickettii</i>	BC 3323	-	-
<i>Pseudomonas pseudoalcaligenes</i>	DSM 50188	-	-
<i>Pseudomonas putida</i>	BC 4941	-	-
<i>Pseudomonas putida</i>	DSM 291	-	-
<i>Pseudomonas putida</i>	DSM 548	-	-
<i>Pseudomonas putida</i>	DSM 549	n.p.	-
<i>Pseudomonas putida</i> (<i>ovalis</i>)	ATCC 950	-	-
<i>Pseudomonas stutzeri</i>	BC 4940	-	-
<i>Pseudomonas syringae</i>	DSM 10604	-	-
<i>Citrobacter amalonaticus</i>	DSM 4593	-	n.p.
<i>Enterobacter aerogenes</i>	DSM 30053	-	n.p.
<i>Escherichia coli</i>	ATCC 8739	-	n.p.
<i>Escherichia hermanii</i>	DSM 4560	-	n.p.
<i>Klebsiella pneumoniae</i>	BC 5362	-	n.p.
<i>Klebsiella terrigena</i>	BC 4700	-	n.p.
<i>Proteus vulgaris</i>	DSM 2024	-	n.p.
<i>Providencia stuartii</i>	BC 5950	-	n.p.
<i>Salmonella Anatum</i>	BC 2284	-	n.p.

BC: BioteCon strain collection; n.p.: not performed.

Patent claims

1. Nucleic acid molecule obtainable by starting from a plurality of strains belonging to, on the one hand, a to-be-detected group of bacteria of the *Pseudomonas* genus and, on the other hand, not-to-be-detected bacteria,
 - (a) isolating, in a manner known *per se*, genomic DNA from a strain of the mentioned bacteria (first strain),
 - (b) amplifying, in a manner known *per se*, the 23S/5S intergenic region, optionally together with the directly adjacent 23S region and/or the directly adjacent 5S region, and obtaining the amplification product (first amplification product),
 - (c) in accordance with steps (a) and (b) in each case, isolating genomic DNA using a second, third, . . . and/or n^{th} strain of the mentioned bacteria, amplifying the 23S/5S intergenic region, optionally together with the directly adjacent 23S region and/or the directly adjacent 5S region, and obtaining the amplification product (second, third, . . . n^{th} amplification product),
 - (d) determining, in a manner known *per se*, the DNA sequence of amplification products obtained according to (b) and (c), and comparing the DNA sequence of the amplification product according to (b) with the DNA sequence of one or more amplification products according to (c), and
 - (e) obtaining, as a primer or probe, in a manner known *per se*, a nucleic acid molecule by means of which the to-be-detected group of bacteria of the *Pseudomonas* genus can be distinguished from not-to-be-detected bacteria, on the basis of differences at at least one nucleotide position in the sequence region of the nucleic acid molecule.
2. Nucleic acid molecule according to claim 1, obtainable by starting from strains belonging to, on the one hand, to-be-

detected bacteria of the *Pseudomonas* genus and, on the other hand, not-to-be-detected bacteria of a genus (genera) other than *Pseudomonas*.

3. Nucleic acid molecule obtainable by starting from a plurality of strains belonging to a to-be-detected group and a not-to-be-detected group of bacteria of the *Pseudomonas* genus,

- (a) isolating, in a manner known *per se*, genomic DNA from a *Pseudomonas* strain of those groups (first strain),
- (b) amplifying, in a manner known *per se*, the 23S/5S intergenic region, optionally together with the directly adjacent 23S region and/or the directly adjacent 5S region, and obtaining the amplification product (first amplification product),
- (c) in accordance with steps (a) and (b) in each case, isolating genomic DNA using a second, third, . . . and/or n^{th} *Pseudomonas* strain of those groups, amplifying the 23S/5S intergenic region, optionally together with the directly adjacent 23S region and/or the directly adjacent 5S region, and obtaining the amplification product (second, third, . . . n^{th} amplification product),
- (d) determining, in a manner known *per se*, the DNA sequence of amplification products obtained according to (b) and (c), and comparing the DNA sequence of the amplification product according to (b) with the DNA sequence of one or more amplification products according to (c), and
- (e) obtaining, as a primer or probe, in a manner known *per se*, a nucleic acid molecule by means of which the to-be-detected group of bacteria of the *Pseudomonas* genus can be distinguished from the not-to-be-detected group of bacteria of the *Pseudomonas* genus on the basis of differences at at least one nucleotide position in the sequence region of the nucleic acid molecule.

4. Nucleic acid molecule according to claim 1 or 3, obtainable by starting from strains belonging to a to-be-detected group of bacteria of the species *Pseudomonas aeruginosa* and a not-to-be-detected group of bacteria of other species.

5. Nucleic acid molecule, especially according to one of the preceding claims, of SEQ ID NO 1 or the sequence complementary thereto.

6. Nucleic acid molecule having a shortened sequence compared with a nucleic acid molecule according to claim 5, namely the sequence of the region or in the region of the nucleotide positions 12 to 131.

7. Nucleic acid molecule having a shortened sequence compared with a nucleic acid molecule according to claim 5, namely
(i) SEQ ID NO 3 or
(ii) SEQ ID NO 4 or
(iii) SEQ ID NO 5 or
(iv) the sequence complementary to each of (i), (ii) and (iii).

8. Nucleic acid molecule of SEQ ID NO 2 or the sequence complementary thereto.

9. Nucleic acid molecule **characterised** in that, in respect of its sequence in at least 10 successive nucleotides of its nucleotide chain,

(i) it is identical to a nucleic acid molecule according to one of the preceding claims or

- (ii) it corresponds to a nucleic acid molecule according to one of the preceding claims in 9 out of 10 successive nucleotides or
- (iii) it corresponds to a nucleic acid molecule according to one of the preceding claims in 8 out of 10 successive nucleotides or
- (iv) it is at least 90 % homologous to a nucleic acid molecule according to one of the preceding claims.

10. Nucleic acid molecule according to claim 9, **characterised** in that it is from 10 to 250, and preferably from 15 to 30, nucleotides long.

11. Nucleic acid molecule according to one of the preceding claims, **characterised** in that it is single-stranded or double-stranded.

12. Nucleic acid molecule according to one of the preceding claims, **characterised** in that it is present

- (i) as DNA or
- (ii) as RNA corresponding to (i) or
- (iii) as PNA,

the nucleic acid molecule where appropriate having been modified in a manner known *per se* for analytical detection processes, especially those based on hybridisation and/or amplification.

13. Nucleic acid molecule according to claim 12, characterised in that the nucleic acid molecule has been modified in such a manner that up to 20 % of the nucleotides of at least 10 successive nucleotides of its nucleotide chain, especially 1 or 2 nucleotides, have been replaced by analogous building blocks known *per se* as probes and/or

primers, especially by nucleotides that do not occur naturally in bacteria.

14. Nucleic acid molecule according to claim 12 or 13, **characterised** in that the nucleic acid molecule has been modified or labelled or additionally modified or labelled in such a manner that it comprises, in a manner known *per se* for analytical detection processes, one or more radioactive groups, coloured groups, fluorescent groups, groups for immobilisation on a solid phase and/or groups for an indirect or direct reaction, especially for an enzymatic reaction, preferably using antibodies, antigens, enzymes and/or substances having an affinity for enzymes or enzyme complexes, and/or otherwise modifying or modified groups of nucleic-acid-like structure.

15. One or more nucleic acid molecules according to one of the preceding claims in the presence of optional auxiliary substances and in the form of a kit for analytical detection processes, especially for the detection of bacteria of the *Pseudomonas* genus.

16. Use of one or more nucleic acid molecules according to one of claims 1 to 14 or in the form of a kit according to claim 15 for detection of the presence or absence of bacteria belonging to a group of bacteria of the *Pseudomonas* genus.

17. Use according to claim 16, characterised in that the group of bacteria of the *Pseudomonas* genus includes various strains of *Pseudomonas aeruginosa* or is made up from those strains.

18. Use according to claim 17, characterised in that the group of bacteria of the *Pseudomonas* genus is composed exclusively of *Pseudomonas aeruginosa* strains.
19. Use according to one of claims 16 to 18, **characterised** in that nucleic acid hybridisation and/or nucleic acid amplification is/are carried out.
20. Use according to claim 19, **characterised** in that, as nucleic acid amplification, a polymerase chain reaction is carried out.
21. Use according to one of claims 16 to 20, **characterised** in that the detection is carried out by distinguishing the to-be-detected bacteria from not-to-be-detected bacteria on the basis of differences in the genomic DNA and/or RNA at at least one nucleotide position in the region of a nucleic acid molecule according to one of claims 1 to 14.
22. Use according to claim 21, **characterised** in that distinguishing is carried out on the basis of differences in the region of a nucleic acid molecule according to claim 5.

Abstract

The present invention relates to a nucleic acid molecule or molecules and to a process for the detection of bacteria of the *Pseudomonas* genus, especially *Pseudomonas aeruginosa*. The invention relates also to a test kit or kits for carrying out the said detection processes.

PTO/SB/01 (6-95)
Approved for use through 9/30/98 OMB 0651-0032

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Type a plus sign (+) inside this box → +

0010-PTO
Rev. 6/95U.S. Department of Commerce
Patent and Trademark Office

DECLARATION FOR UTILITY OR DESIGN PATENT APPLICATION

Declaration OR Declaration
Submitted Submitted after
with Initial Filing Initial Filing

Attorney Docket Number 2727-102

First Named Inventor Cornelia Berghof

COMPLETE IF KNOWN

Application Number 09/508,238

Filing Date

Group Art Unit

Examiner Name

As a below-named Inventor, I hereby declare that:

My residence, post office address, and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention set forth.

"Amino Acid Sequences and Method for Isolating Bacteria from the Type Genus *Pseudomonas*"

(Title of the Invention)

the specification of which

is attached hereto
OR

was filed on (MM/DD/YYYY) 09/09/1998

as United States Application Number or PCT International

(USSN 09/508,238)

Application Number PCT/EP98/05738

and was amended on (MM/DD/YYYY)

(if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in Title 35 Code of Federal Regulations, §1.56

I hereby claim foreign priority benefits under Title 35, United States Code §119 (a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate, or §365 (a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Foreign Filing Date (MM/DD/YYYY)	Priority Not Claimed	Certified Copy Attached? YES NO
197 39 611.9	Germany (DE)	09/09/1997	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>

Additional foreign application numbers are listed on a supplemental priority sheet attached hereto.

I hereby claim the benefit under Title 35, United States Code³ 119(e) of any United States provisional application(s) listed below.

Application Number(s)	Filing Date (MM/DD/YYYY)	Additional provisional application numbers are listed on a supplemental priority sheet attached hereto.
		<input type="checkbox"/>

Burden Hour Statement: This form is estimated to take 4 hours to complete. Time will vary depending upon the needs of the individual case. Any comments or the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

DECLARATION

Page 2

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s), or §365(c) of any PCT international application designating the United States of America, listed below and, if such as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code §112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations §1.56 which becomes available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. Parent Application Number	PCT Parent Number	Parent Filing Date (MM/DD/YYYY)	Parent Patent Number <i>(if applicable)</i>

Additional U.S. or PCT international application numbers are listed on a supplemental priority sheet attached hereto.

As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and to conduct all business at the Patent and Trademark Office connected therewith:

<input type="checkbox"/> Firm Name OR <input type="checkbox"/> List attorney(s) and/or agent(s) name and registration number below	<input type="checkbox"/> Customer or Label Number
Joseph C. Sullivan	18,720
Gerald Levy	24,419
Ronald R. Santucci	128,988
Ronald E. Brown	32,200
John F. Gulbin	33,180
Richard J. Danyko	33,672

Additional attorney(s) and/or agent(s) named on a supplemental sheet attached hereto.

Please direct all correspondence to Customer or Label Number OR Fill in correspondence address below

Name Ronald R. Santucci
Address Pitney, Hardin, Kipp & Szuch, LLP
Address 711 Third Avenue, 20th Floor
City New York, State NY, ZIP 10017
Country U.S.A. Telephone 212-687-6000 Fax 212-682-3484

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Name of Sole or First Inventor: A petition has been filed for this unsigned inventor

Given Name	<u>Cornelia</u>	Middle Initial	Family Name	<u>Berghof</u>	Suffix e.g. Jr.
------------	-----------------	----------------	-------------	----------------	-----------------

Inventor's Signature Berghof Date 26. April 2000

Residence: City Berlin State Det Country Germany Citizenship German

Post Office Address Rhodelaenderweg 85,

Post Office Address

City Berlin State Zip D-12355 County Germany Applicant Authority

Additional inventors are being named on supplemental sheet(s) attached hereto

(Declaration for Utility or Design Patent Application (PTO/SB/01) [1-10.1]—page 2 of 4)

DECLARATION

ADDITIONAL INVENTOR(S)
Supplemental Sheet


Name of Additional Joint Inventor, if any:				<input type="checkbox"/> A petition has been filed for this unsigned inventor		
Given Name	Alexander	Middle Initial	Family Name	Gasch		
Inventor's Signature	<i>Alexander Gasch</i>				Date	12.3.2000
Residence: City	Berlin DE	State	Country	Germany	Citizenship German	
Post Office Address	Steegerstr. 71,					
Post Office Address						
City	Berlin	State	Zip	D-13359	Country	Germany
Name of Additional Joint Inventor, if any:				<input type="checkbox"/> A petition has been filed for this unsigned inventor		
Given Name	Anja S.	Middle Initial	Family Name	Braeuer		
Inventor's Signature	<i>Anja Braeuer</i>				Date	17.04.00
Residence: City	Berlin DE	State	Country	Germany	Citizenship German	
Post Office Address	Residenzstr. 100,					
Post Office Address						
City	Berlin	State	Zip	D-13409	Country	Germany
Name of Additional Joint Inventor, if any:				<input type="checkbox"/> A petition has been filed for this unsigned inventor		
Given Name	Cordt	Middle Initial	Family Name	Groenewald		
Inventor's Signature	<i>Cordt Groenewald</i>				Date	10.04.00
Residence: City	Berlin DE	State	Country	Germany	Citizenship German	
Post Office Address	Elberfelder Str. 12,					
Post Office Address						
City	Berlin	State	Zip	D-10555	Country	Germany
Name of Additional Joint Inventor, if any:				<input type="checkbox"/> A petition has been filed for this unsigned inventor		
Given Name	Freimut	Middle Initial	Family Name	Wilborn		
Inventor's Signature	<i>Freimut & Wilborn</i>				Date	04.04.2000
Residence: City	Berlin DE	State	Country	Germany	Citizenship German	
Post Office Address	Neue Kantstr. 9,					
Post Office Address						
City	Berlin	State	Zip	D-14057	Country	Germany
<input checked="" type="checkbox"/> Additional inventors are being named on supplemental sheet(s) attached hereto						

(Declaration for Utility or Design Patent Application (PTO/SB/01) [1-10.1]—page 3 of 4)

DECLARATION				ADDITIONAL INVENTOR(S) Supplemental Sheet			
Name of Additional Joint Inventor, if any:				<input type="checkbox"/> A section has been filed for this unsigned inventor			
Given Name	Arndt	Middle Initial	Family Name	Bolts	Suffix		
Inventor's Signature							
Date	26 April 2000						
Residence City	Rostock	State	Zip	Country	Germany	Classification	German
Post Office Address	Schroederstr. 39, G. Hauptmains. 8						
Post Office Address							
City	Rostock	State	Zip	Country	Germany	Applicant Authority	
Name of Additional Joint Inventor, if any:				<input type="checkbox"/> A section has been filed for this unsigned inventor			
Given Name		Middle Initial	Family Name		Suffix		
Inventor's Signature							
Date							
Residence City		State	Zip	Country		Classification	
Post Office Address							
Post Office Address							
City		State	Zip	Country		Applicant Authority	
Name of Additional Joint Inventor, if any:				<input type="checkbox"/> A section has been filed for this unsigned inventor			
Given Name		Middle Initial	Family Name		Suffix		
Inventor's Signature							
Date							
Residence City		State	Zip	Country		Classification	
Post Office Address							
Post Office Address							
City		State	Zip	Country		Applicant Authority	
Name of Additional Joint Inventor, if any:				<input type="checkbox"/> A section has been filed for this unsigned inventor			
Given Name		Middle Initial	Family Name		Suffix		
Inventor's Signature							
Date							
Residence City		State	Zip	Country		Classification	
Post Office Address							
Post Office Address							
City		State	Zip	Country		Applicant Authority	
<input type="checkbox"/> Additional inventors are being named on Supplemental sheet(s) attached hereto.							

(Declaration for Utility or Design Patent Application (PTO/SB/01) (1-10.1)—page 4 of 4)

United States Patent & Trademark Office
Office of Initial Patent Examination -- Scanning Division



Application deficiencies were found during scanning:

Page(s) _____ of _____ were not present
for scanning. (Document title)

Page(s) _____ of _____ were not present
for scanning. (Document title)

Scanned copy is best available.

declaration

of verified statement,